3B Blackbio DX Ltd
3B Blackbio DX Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on 3B Blackbio DX Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Q2 FY 2025-26 EBITDA: Not explicitly stated for standalone or consolidated; H1 EBITDA (3B standalone) increased from ₹3,387.70 Lakh (H1 FY 2024-25) to ₹3,618.54 Lakh (H1 FY 2025-26).
From 3B Blackbio DX Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25.
- Exports in Q2 FY 2025-26: ₹496.71 Lakh vs. ₹366.50 Lakh in Q2 FY 2024-25.
- TRUPCR Europe Ltd (TPE) Q2 sales: GBP 404,900 vs. GBP 420,435 last year, slight decrease due to summer holidays.
- H1 FY 2025-26 revenue from operations: ₹4151.99 Lakh vs. ₹5038.89 Lakh in H1 FY 2024-25 (3B standalone MDx business).
- Consolidated H1 2025-26 revenue: ₹5613.67 Lakh vs. ₹4858.10 Lakh previous year.
- Export growth projected at 20–25%.
- TPE full-year growth expected at 20–25%.
2 more points management made on revenue & sales performance
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company acquired Coris BioConcept SRL, Belgium, for £2.15M upfront plus £0.615M earn-out, completed on August 29, 2025, marking its first acquisition to strengthen market credibility (Page 29, 42).
- Coris operates at ~65% capacity, with potential to scale up during seasonal spikes; no specific new plant or expansion capex mentioned (Page 42).
- Funds will be deployed in a joint venture in Manchester, UK, depending on need; no specific amount or timeline provided (Page 42).
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The presentation does not explicitly state the total order book, order inflow, or pending orders in numeric terms.
- It mentions "strong order inflow" from the Middle East, indicating growing market traction (Page 21).
- Signing of long-term contracts (2-3 years) covering 20%-25% of total revenue under the Reagent-Rental Model demonstrates stability and steady business (Page 41).
- The Coris BioConcept acquisition is expected to contribute improved sales and positive EBITDA in H2, tied to its contracts including a €1.0 million government project in Belgium supplied in Nov-Dec (Page 29).
2 more points management made on order book & pipeline
3B Blackbio DX Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio DX Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Unihealth Hospitals Ltd (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
- Indegene (Q2 FY26)
Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term…
- Dr Lal Pathlabs Ltd (Q2 FY26)
Sustained 11%-12% revenue growth without price hikes is planned, driven by increased patient volume and revenue per patient. Key concall takeaways from Dr Lal…
- Health.Global (Q2 FY26)
Medium-term goal to realize Rs.4,000 crore revenue potential over 4-5 years from current Rs.2,200 crore at existing price points and optimized utilization. Key…
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q2 FY26 results?
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Q2 FY 2025-26 EBITDA: Not explicitly stated for standalone or consolidated; H1 EBITDA (3B standalone) increased from ₹3,387.70 Lakh (H1 FY 2024-25) to ₹3,618.54 Lakh (H1 FY 2025-26).
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company acquired Coris BioConcept SRL, Belgium, for £2.15M upfront plus £0.615M earn-out, completed on August 29, 2025, marking its first acquisition to strengthen market credibility (Page 29, 42).
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.